ABSTRACT: The objectives of this investigation were to evaluate the release of dihydrotestosterone (DHT) 
INTRODUCTION
onsiderable evidence has accumulated during the past few years to C indicate that dihydrotestosterone (DHT), a metabolite of testosterone (T), may be involved in certain aspects of androgen action in the accessory organs of the male reproductive system. In the adult male rat, DHT formation from T occurs at appreciable rates only in known T target tissues [1, 2] . Wilson and Lasnitzki reported, after following the administration of radioactive T to intact animals, that the major fraction of the isotope which is bound to the nuclei of the known target tissue is in the form of DHT [2] . Both in vitro and in vivo studies have established that DHT is equal or greater in potency to T itself [3, 4] . To date, long-term in vivo (12 months) delivery of DHT in a sustained manner has not been investigated. Data obtained from previous studies has shown that steroid (s) filled ceramic devices provide a unique delivery system for delivering agent(s) of choice. The daily release rates of chemicals or biologicals (C/B) by subcutaneous or intraperitoneal implants of ceramic reservoirs make it possible to provide a means of administering small but effective daily dosages over extended periods of time following implantation (SC or IP) of single or multiple ceramic capsule(s) [5] [6] [7] [8] [9] [10] [11] . The purposes of this study were: (1) to compare the release rate of dihydrotestosterone (DHT) from nonimpregnated and poly(lactic acid) (PLA) impregnated ALCAP ceramic reservoirs implanted in male rats, and (2) Figure 1 are the release rates of DHT from PLA impregnated and nonimpregnated ALCAP ceramics implanted in rats for the 12 month duration of the study. The rate of release of DHT from nonimpregnated ceramics was significantly higher than that of PLA impregnated ceramics. Data obtained from previous studies [5] (Figure 2a ) revealed that at the end of one month the physiological changes observed were: decreased tubular diameters, arrested spermatogenesis, and decreased production of spermatozoa (oligospermia). Three months after the implantation of DHT containing ceramic capsules, spermatozoa could not be detected in the seminiferous tubules of the rat testes (azoospermia). In adult animals treated with DHT, suppression of spermatogenesis has been shown to be associated with a decrease in circulating levels of testosterone [13] . In castrated rats, administration of DHT results in restoring and maintaining the weights of accessory sex organs [14] . Results of this investigation confirm previous findings and suggest that the decrease in spermatogenic activity could be due to suppression of gonadotrophins and consequent decrease in intratesticular testosterone. Figure 2 . Reproductive organ weights (mean t SD) of male control rats, male rats implanted with two empty &dquo;sham&dquo; ALCAP capsules, and male rats implanted with PLA impregnated (I-ALCAP) and nonimpregnated ALCAP (N-ALCAP) ceramic capsules containing DHT (40 mg each) for treatment periods of 3, 6, 9, and 12 months. Figure 2 are the weights of epididymis (head-body), obtained from rats implanted with DHT filled ALCAP ceramics. These were significantly different than epididymis obtained from shams and intact control rats. Since DHT is the only nuclear bound androgen in the rat epididymis, the reduction in epididymal mass could be due to the low endogenous DHT levels. Histopathological evaluations (Figures 2b-2d ) of testes and accessory organs in this study suggest that the suppression of epididymal mass may be due to the decreased growth of the epididymal ducts (Figure 2b ). Epididymal fluid analysis showed that DHT released from ALCAP ceramics induced oligospermia in rats after one month, and that the azoospermia achieved at the end of three months was maintained up to 12 months. These obser- vations were supported by data obtained from hormonal blood analysis. In comparison to circulating LH and FSH levels of sham and control rats, the serum LH and FSH levels of experimental rats decreased significantly for the entire duration of the study (Figure 3 Figure 2 are the weights of prostates in experimental rats. These were regressed at the end of the three months post-implantation in comparison to sham and control groups. At the end of six, nine, and twelve month intervals, the weights of the seminal vesicles and ventral prostates in experimental rats were not significantly different from those of sham and control rats. Several investigators have reported that the growth of the prostate in rats is stimulated by DHT, and it appears that DHT is the principal intracellular androgen of the prostate [15] [16] [17] [18] [19] . The role of DHT in human prostatic growth is supported by the fact that absence of significant prostatic development is seen in subjects who have a deficiency of the enzyme 5-alpha-reductase in the presence of high levels of circulating T [15-191. Results of this investigation (Figure 2d) show that the amount of DHT released from ALCAP ceramics was capable of maintaining the normal function of prostatic tissues.
Shown in
The effect of sustained release of appropriate amounts of DHT from ceramics on other vital tissues was also examined. There were no significant differences between the weights of the kidneys and adrenals obtained from experimental, sham, and control rats (Figure 4 ). The spleen, heart, and body weight were unaffected by the amount of DHT released from the ceramic implants (Figures 4 and 5 ).
CONCLUSIONS
The overall observations made during this investigation suggest that: (1) 4 . Vital organ weights (mean + ) of male control rats, male rats implanted with two empty &dquo;sham&dquo; ALCAP capsules, and male rats implanted with PLA impregnated and nommpregnated ALCAP ceramic capsules containing DHT (40 mg) for treatment periods of 3, 6, 9 and 12 months Figure 5 . Body weights of male control rats, male rats implanted with two empty &dquo;sham&dquo; ALCAP capsules and male rats implanted with PLA impregnated and nonimpregnated ALCAP ceramic capsules contammg T DHT (40 mg) for treatment periods of 3, 6, 9 and 
